Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.
In a study that appears on the Proceedings of the National Academy of Sciences, researchers found that a single dose of a small interfering RNA (siRNA), a chemical cousin of DNA, lowered cholesterol levels up to 60 percent in rodents, with the effects lasting for weeks. This result indicated that the RNA interference, or RNAi, mechanism could provide a new tactic for treating high cholesterol. Similar treatments in four nonhuman primates, conducted off-site by a certified contract research organization, produced an average 56 percent drop in low-density lipoprotein cholesterol levels in the animals’ blood.